Case Study: Navigating the preclinical “Valley of Death”- Scaling from Discovery to Tox Batch

26/03/2026

An update on the future of Apex Molecular.

It is with great sadness that we announce the closure of Apex Molecular.

Unfortunately, the persistently challenging market conditions have made it impossible for the business to continue and after reviewing the options to the business, this solvent closure allows the company to conclude remaining projects and commitments over the next months.

Regrettably the closure will result in the loss of all jobs. We are no longer accepting project enquiries, have initiated the closure of the business and over the next 2 months we will exit our facilities.

While this marks the end of our journey, we depart with immense pride in the contributions we have made to the industry across the Life Sciences, Agtech, and the Applied Materials sectors.

We are incredibly proud of the work we have accomplished and the scientific milestones we have supported, particularly in preclinical drug discovery.

We want to extend our deepest gratitude to our customers, partners/collaborators, and most importantly, our exceptional team, both past and present. Their skills, innovation, communication and dedication have been the heartbeat of the company, and the reason customers came back with new projects again and again.

We are committed to handling this closure with the same integrity and transparency that defined our operations over the last 15 years.

Thank you to everyone who has supported our journey.